Is Buying 52-Week Stock Like Emergent BioSolutions Inc. (EBS) a Winning Strategy?

June 15, 2018 - By Linda Rogers

Emergent BioSolutions Inc. (NYSE:EBS) Logo

Investors sentiment decreased to 1.77 in Q1 2018. Its down 0.25, from 2.02 in 2017Q4. It worsened, as 10 investors sold Emergent BioSolutions Inc. shares while 65 reduced holdings. 56 funds opened positions while 77 raised stakes. 38.34 million shares or 3.95% more from 36.89 million shares in 2017Q4 were reported.
136,638 are held by Bogle Inv Mngmt Lp De. Ameriprise Fincl has invested 0.01% in Emergent BioSolutions Inc. (NYSE:EBS). 1.73 million were reported by State Street Corporation. Employees Retirement Of Texas reported 116,000 shares. 9,731 were reported by Mason Street Advsr Lc. Phocas Fincl Corporation holds 153,106 shares. Loomis Sayles Ltd Partnership holds 0% in Emergent BioSolutions Inc. (NYSE:EBS) or 179 shares. Balyasny Asset Management Ltd, a Illinois-based fund reported 6,961 shares. Renaissance Limited reported 1.87M shares stake. Hotchkis And Wiley Cap Mngmt Ltd invested in 19,507 shares. Moreover, Envestnet Asset Management has 0% invested in Emergent BioSolutions Inc. (NYSE:EBS) for 7,302 shares. Systematic Fincl Management Lp holds 26,315 shares or 0.03% of its portfolio. Chicago Equity Prns Ltd Liability holds 0.19% of its portfolio in Emergent BioSolutions Inc. (NYSE:EBS) for 115,560 shares. Dana Invest Advsrs Inc holds 0.29% or 124,320 shares in its portfolio. Alps Advsrs invested in 75,360 shares.

Since January 2, 2018, it had 0 insider purchases, and 11 sales for $4.28 million activity. Havey Adam had sold 1,898 shares worth $93,951. 7,342 Emergent BioSolutions Inc. (NYSE:EBS) shares with value of $389,126 were sold by Richard Ronald. The insider Zoon Kathryn C sold $70,434. Abdun-Nabi Daniel also sold $1.05M worth of Emergent BioSolutions Inc. (NYSE:EBS) shares. 5,000 shares were sold by JOULWAN GEORGE A, worth $264,448 on Monday, June 11.

The stock of Emergent BioSolutions Inc. (NYSE:EBS) hit a new 52-week high and has $54.50 target or 4.00 % above today’s $52.40 share price. The 9 months bullish chart indicates low risk for the $2.61B company. The 1-year high was reported on Jun, 15 by Barchart.com. If the $54.50 price target is reached, the company will be worth $104.44M more.
The 52-week high event is an important milestone for every stock because it shows very positive momentum and is time when buyers come in. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock.

The stock decreased 5.82% or $3.24 during the last trading session, reaching $52.4. About 183,150 shares traded. Emergent BioSolutions Inc. (NYSE:EBS) has risen 65.53% since June 15, 2017 and is uptrending. It has outperformed by 52.96% the S&P500.

Analysts await Emergent BioSolutions Inc. (NYSE:EBS) to report earnings on August, 2. They expect $1.02 earnings per share, up 684.62 % or $0.89 from last year’s $0.13 per share. EBS’s profit will be $50.82M for 12.84 P/E if the $1.02 EPS becomes a reality. After $-0.03 actual earnings per share reported by Emergent BioSolutions Inc. for the previous quarter, Wall Street now forecasts -3,500.00 % EPS growth.

Emergent BioSolutions Inc. (NYSE:EBS) Ratings Coverage

Among 5 analysts covering Emergent BioSolutions (NYSE:EBS), 3 have Buy rating, 0 Sell and 2 Hold. Therefore 60% are positive. Emergent BioSolutions has $6200 highest and $55 lowest target. $59’s average target is 12.60% above currents $52.4 stock price. Emergent BioSolutions had 5 analyst reports since January 24, 2018 according to SRatingsIntel. The stock of Emergent BioSolutions Inc. (NYSE:EBS) earned “Buy” rating by Singular Research on Tuesday, February 27. The firm has “Hold” rating given on Tuesday, April 24 by Wells Fargo. The company was initiated on Monday, June 11 by Cantor Fitzgerald.

More notable recent Emergent BioSolutions Inc. (NYSE:EBS) news were published by: Streetinsider.com which released: “Cantor Fitzgerald Starts Emergent BioSolutions (EBS) at Overweight” on June 11, 2018, also Globenewswire.com with their article: “Emergent BioSolutions Announces $50 Million Expansion of Baltimore Fill/Finish Facility” published on June 07, 2018, Benzinga.com published: “Benzinga’s Top Upgrades, Downgrades For June 13, 2018” on June 13, 2018. More interesting news about Emergent BioSolutions Inc. (NYSE:EBS) were released by: Globenewswire.com and their article: “Consolidated Research: 2018 Summary Expectations for PGT, National Commerce, CrossAmerica Partners LP …” published on May 24, 2018 as well as Streetinsider.com‘s news article titled: “Emergent BioSolutions (EBS) in Collanoration with Profectus BioSciences Inc. Secures $25M Contract from CEPI to …” with publication date: May 24, 2018.

Emergent BioSolutions Inc. focuses on the development, manufacture, and commercialization of medical countermeasures that address public health threats. The company has market cap of $2.61 billion. The Company’s products address public health threats primarily chemical, biological, radiological, nuclear, and explosive-related threats, as well as infectious diseases. It has a 30.72 P/E ratio. The companyÂ’s marketed products include BioThrax, an anthrax vaccine; Anthrasil, a polyclonal antibody for the treatment of inhalational anthrax; BAT for the treatment of botulinum disease; vaccinia immune globulin intravenous that addresses adverse events from smallpox vaccination; reactive skin decontamination lotion kit for the removal or neutralization of chemical warfare agents; and Trobigard, an auto-injector device designed for intramuscular self-injection of atropine sulfate and obidoxime chloride.

Emergent BioSolutions Inc. (NYSE:EBS) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.